Skip to content

Robot-assisted Versus Laparoscopic Surgery for Right-sided Colon Cancer (READY): A Multicenter Randomized Controlled Trial

Robot-assisted Versus Laparoscopic Surgery for Right-sided Colon Cancer (READY): A Multicenter Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800017146
Enrollment
Unknown
Registered
2018-07-13
Start date
2019-01-01
Completion date
Unknown
Last updated
2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Right-sided colon cancer

Interventions

B(control group):Laparoscopic surgery

Sponsors

the First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18 to 80 years; (2) The tumor is located in the right-sided colon: ileus, ascending colon, liver curvature of colon , right 1/3 of transverse colon; (3) Pathologic biopsy confirmed the right-sided colon adenocarcinoma; (4) Preoperative clinical stage: locally advanced right-sided colon adenocarcinoma(cT2-4,N0-2,M0AJCC-8); (5) R0 results are expected from right hemicolectomy and regional lymph node dissection; (6) Preoperative ECOG physical state score: 0/1; (7) Preoperative ASA score: I-III; (8) Patient or family members understand the research program and are willing to participate in this study and sign written informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe mental illness; 2. Emergency surgery for acute intestinal obstruction, bleeding and perforation in the right-sided colon adenocarcinoma; 3. Multiple primary colorectal malignant tumors; 4. Family adenomatosis (FAP), Lynch syndrome, inflammatory bowel disease; 5. Patients with right-sided colon adenocarcinoma who have undergone new adjuvant therapy before surgery; 6. History of abdominal surgery; 7. Pregnant or lactating women; 8. There were other malignant diseases within 5 years; 9. There were simultaneous surgical treatment for other diseases; 10. There were continuous systemic corticosteroid therapy within 1 month; 11. There were unstable angina or myocardial infarction within 6 months; 12. There were cerebral infarction or cerebral hemorrhage within 6 months; 13. Pulmonary function test FEV1< 50%.

Design outcomes

Primary

MeasureTime frame
3-year disease-free survival;

Secondary

MeasureTime frame
3-year overall survival;5-year disease-free and overall survival;3/5-year locoregional recurrence rate;postoperative complication rate;operative duration;estimated blood loss;postoperative complications;conversion to open surgery;Postoperative recovery time;length of postoperative hospital stay;postoperative 30-day mortality rate;Postoperative quality of life;

Countries

China

Contacts

Public ContactTaiyuan Li

the First Affiliated Hospital of Nanchang University

jylitaiyuan@sina.com+86 0791-88694893

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026